




Review

Role of the Gut–Liver Axis in the Pathobiology of Cholangiopathies: Basic and Clinical Evidence

Maria Consiglia Bragazzi ^{1,*}, Rosanna Venere ¹, Anthony Vignone ² , Domenico Alvaro ²
and Vincenzo Cardinale ²

¹ Department of Medical-Surgical Sciences and Biotechnology, Sapienza University of Rome Polo Pontino, 04100 Roma, Italy

² Department of Translational and Precision Medicine, Sapienza University of Rome, 04100 Roma, Italy

* Correspondence: mariaconsiglia.braga@uniroma1.it

Abstract: The “Gut–Liver Axis” refers to the physiological bidirectional interplay between the gut and its microbiota and the liver which, in health, occurs thanks to a condition of immune tolerance. In recent years, several studies have shown that, in case of a change in gut bacterial homeostasis or impairment of intestinal barrier functions, cholangiocytes, which are the epithelial cells lining the bile ducts, activate innate immune responses against gut-derived microorganisms or bacterial products that reach the liver via enterohepatic circulation. Intestinal dysbiosis or impaired intestinal barrier functions cause cholangiocytes to be exposed to an increasing amount of microorganisms that can reactivate inflammatory responses, thus inducing the onset of liver fibrosis. The present review focuses on the role of the gut–liver axis in the pathogenesis of cholangiopathies.

Keywords: Gut liver Axis; microbiota; choalngiopathies



Citation: Bragazzi, M.C.; Venere, R.; Vignone, A.; Alvaro, D.; Cardinale, V. Role of the Gut–Liver Axis in the Pathobiology of Cholangiopathies: Basic and Clinical Evidence. *Int. J. Mol. Sci.* **2023**, *24*, 6660. <https://doi.org/10.3390/ijms24076660>

Academic Editor: Stephen Bustin

Received: 28 February 2023

Revised: 23 March 2023

Accepted: 29 March 2023

Published: 3 April 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. The “Gut–Liver Axis”

The concept of the “gut–liver axis”, was introduced by Marshall in 1998, and it refers to the close anatomical and functional relationship between the gut and the liver. The interaction between these organs is bidirectional and is characterized by the transfer, to the liver, of molecules associated with the intestinal microbiota, starting from the intestine, thanks to the vascular pathway of the portal vein, and, at the same time, by the hepatic feedback pathway of bile and antibody secretion in the intestine [1]. In health, there is a mechanism defined as “immune intolerance,” thanks to which part of the intestinal mycorbic antigens enter the portal blood circulation and are recognized by the immune cells of the liver without eliciting an immunological response [2].

In particular, in the gut, the mucosal barrier separates the host immunity and the intestinal microbiota in order to avoid an unfavorable interaction between the two. The luminal side of the intestine is lined with epithelial cells which, promote the absorption of water and nutrients, and also play an important role in generating a physical and chemical barrier to protect the mucosa from commensal and pathogenic microorganisms [3]. Regenerating islet-derived protein (Reg3 γ) and cyclic adenosine monophosphate (AMP) secreted by Paneth cells constitute the chemical barrier and mainly contribute to the separation between intestinal bacteria and intestinal epithelial cells in the small intestine [3]. Instead, in the large intestine hosts the inner mucus layer, composed of polymerized mucin Mucin 2, oligomeric mucus gel-forming (MUC2), which acts as a physical barrier and separates intestinal bacteria from intestinal epithelial cells [3]. The stability of this equilibrium is essential in maintaining intestinal homeostasis [3–5]. The gut microbiota is involved in promoting the digestive process, nutrient absorption, and the production of small chain fatty acids (SCFA). It is also a primary energy source for intestinal epithelial cells (IEC), promoting the stimulation of immune responses through the release of ligands and providing protection against enteropathogens through the production of antimicrobial

peptides (AMPs), which serve as a protective barrier against pathogens from competing for space and food [6,7].

The composition of the gut microbiome is influenced by several factors including diet, age, host genotype, disease state, and antibiotic exposure [7]. The composition of the intestinal microbiota is different for each individual, and there is no optimal composition, even if a healthy host–microorganism balance must be respected. This condition is defined by the term *eubiosis*, and allows metabolic and immune functions to be performed optimally.

In conditions where there is an imbalance in the gut microbial community, in terms of qualitative and quantitative changes, metabolic activity, and topographic distribution, we speak of *dysbiosis* of the gut microbiota [8]. Dysbiosis can disrupt the integrity of the mucosal barrier [9,10]. Indeed, pathological conditions (e.g., a high-fat/high-fructose diet, intestinal inflammation, systemic diseases) promote dysbiosis and increase the permeability of the cellular pathway (tight junction disruption), causing inadequate nutrient absorption and the inability to prevent the translocation of luminal bacteria and their products (also called pathogen-associated molecular patterns or PAMPs), and the reabsorption of damage-associated molecular patterns (DAMPs) [11–14]. Typically, in conditions of dysbiosis, the hyperactivity of the innate immune response leads to an overexpression of M1/M2 type macrophages which, once activated, increase pro-inflammatory events. Moreover, regulatory T cells (Treg) regulate the adaptive immune response by maintaining tolerance to self-antigens and inducing a suppression of excessive activation of immune responses. Insufficient Treg expression can lead to increased levels of Th1 and Th17, facilitating chronic inflammatory responses. In turn, the gut barrier is heavily impaired (vicious circle), leading to systemic effects due to the translocation of bacteria and associated PAMPs or DAMPs [11–14].

In case of changes in intestinal bacterial homeostasis or in the presence of a disease state resulting in impaired intestinal barrier function, an altered composition of gut-derived products reaches the liver via the portal vein, potentially inducing liver inflammation which, in turn, generates subsequent complex responses in liver cells including cholangiocytes [15]. In the liver, microbes and pathogens drive inflammation by acting on receptors on liver sinusoidal endothelial cells, Kupffer cells, hepatic stellate cells, and by activating the NLRP3 inflammasome [16].

2. Biliary Barrier

Bile acids, oxysterols, antigens, endotoxins, and xenobiotics are bile constituents and the major determinants of this harmful bile microenvironment. It is known that the biliary system contrasts this environment with several biochemical systems. Among them, an important role is also exercised by alkaline phosphatase, which has an important function in endotoxin/xenobiotic detoxification. Recent evidence by our group has highlighted the visceral tissue organization of the bile ducts. We have previously discovered that biliary tree stem/progenitor cells (BTSCs) are located at the base of the peribiliary glands (PBGs) of large intrahepatic and extrahepatic bile ducts, and that they differentiate into mature cholangiocytes and goblet cells during migration from the bottom to the top of the glands. In summary, in the biliary tree, the intestinal model characterized by the proliferation of multipotent stem cells within the crypts of Lieberkuhn, by cell migration and by differentiation along the axis of the villi of the crypt, are fundamental for the development and maintenance of the architecture intestinal [17–19]. Evidence demonstrates that, like the gut, the biliary system also has a mechanical, chemical, and immunological barrier which ensures an immunological tolerance towards the commensals [14]. Indeed, the biliary epithelium also shows a wide range of innate immune receptors, such as Toll-like-receptor (TLR) 1 to TLR6 and TLR9. Antimicrobial peptides including human β -defensin-1 and -2 are widely expressed in the intrahepatic biliary tree. Tissue macrophages and liver Kupffer cells, activated by proinflammatory cytokines, induce microbial killing and antigen presentation to T cells and plasma cells in the biliary system. IgA are secreted in the bile by the biliary epithelium [14]. Moreover, specific microorganisms possess tolerance

mechanisms in order to resist bile action. [4]. In the past, bile fluid was previously thought to be sterile. Several studies have documented the presence of bacteria even in the bile ducts in homeostatic conditions [11–13]. The existence of a biliary microbiome in healthy people was first documented in a study conducted by Molinero et al., through the collection of bile samples in patients undergoing gallbladder resections [12]. Results in experimental models on biliary injury demonstrate the crucial role played by the commensal microbiota and its metabolites in protecting against biliary injury and suggest avenues for future biomarker studies and therapeutic interventions in PSC [20].

3. Role of Bile Acids in Gut–Liver Interactions

Bile salts constitute a powerful tool in gut–liver bidirectional interactions and mediate systemic effects throughout their cognate cellular receptor, farnesoid X receptor (FXR), and tumor growth rate 5 (TGR5) [21,22].

FXR regulates the synthesis and transport of bile acids. It is a member of the nuclear metabolic receptor superfamily and, among many functions, by interacting with bile acids (BA), it regulates their synthesis and enterohepatic circulation [21,22]. Recent studies have shown that bile acids, after their transformation into secondary bile acids, signal intestinal epithelium primarily via the FXR. Primary BA from the gut lumen are transported into intestinal epithelial cells where they can bind to FXR, through which they promote the transcription of fibroblast growth factor 19 (FGF-19) [15].

TGR-5, also known as G protein-coupled bile acid receptor 1, is expressed in the liver, and in other organs, such as the intestine [23,24]. It is activated by bile acids, including cholic, chenodeoxycholic, deoxycholic, and lithocholic acid [25]. Similarly to TGR5, even FXR plays an important role in the enterohepatic circulation of cholic acid [26,27]. In turn, it has been documented that the microbiota can modulate signaling through both FXR and TGR-5 via the modification of bile acids [28].

The liver communicates with the gut through the biliary system (the biliary tract connects the liver with the duodenum), and the systemic circulation by releasing bile acids (BA) and systemic inflammatory mediators like cytokines [29]. BAs are molecules synthesized in the liver from cholesterol and then released and reabsorbed in the gut by the microbiota [28]. The amount of BA produced depends on an active feedback loop from the gut to the liver, which is called the enterohepatic circulation [30]. Before being excreted, primary BAs are conjugated with the amino acid glycine and, to a lesser extent, with taurine in humans and subsequently released in the bile. About 90% to 95% of BAs are absorbed at the distal ileum and subsequently transported to the liver, where they are recycled after entering the portal circulation. The remaining parts of the BAs are degraded and biotransformed by microorganisms mainly at the level of intestinal tract, and some of them are excreted by feces [28]. The transformation from primary to secondary BAs (deconjugation and dihydroxylation) is facilitated by bile salt hydrolases (BSH) and 7 α -dehydroxylase expressed by microbes of the gut microbiome including all major phyla (BSH) and the genera *Bacteroides*, *Clostridium*, *Eubacterium*, *Lactobacillus*, and *Escherichia* [15,28]. At the same time, BAs have a key role in shaping the microbiota. This indicates that there is a two-way interaction between bile acids and gut microbiota, as the microbiota affects the metabolism of bile acids [31] and bile acids affect microbiota composition.

4. The Gut–Liver Axis in Cholangiopathies

Cholangiopathies are a group of progressive diseases that affect cholangiocytes, the epithelial cells lining the small bile ducts (interlobular bile ducts; see Primary biliary cholangitis (PBC), Drug-induced liver injury (DILI), small bile duct intrahepatic cholangiocarcinoma (iCCA)) and the large bile ducts (septal, segmental, extrahepatic; see primary sclerosing cholangitis (PSC), IgG4-related cholangitis, large bile duct iCCA, perihilar cholangiocarcinoma (pCCA), distal cholangiocarcinoma (dCCA)). These pathologies are generally chronic, and the pathogenetic processes affecting cholangiocytes in these cases are not yet

fully known. Depending on their nature, these diseases are further subdivided into genetic; autoimmune, which includes PBC, PSC, and IgG4-related cholangitis; malignant, such as cholangiocarcinoma (CCA); or combined hepato-cholangiocarcinoma (CHC), and other categories [32,33]. Ascending cholestasis is a pathological consequence of cholangiopathies in which, although bile is produced by hepatocytes, the bile flow through the intestine is impaired, resulting in the intrahepatic accumulation of bile acids and a consequent state of inflammation in the liver and NF- κ B-mediated production of pro-inflammatory cytokines [34–37]. Elevated levels of hydrophobic bile acids damage the bile duct epithelium and increase luminal pressure until the bile duct ruptures, resulting in hepatocytes being exposed to high concentrations of bile acids and inflammatory infiltration, and consequently, death of the hepatocytes [38].

In health, cholangiocytes are quiescent and participate to the final bile volume and composition. When normal gut bacterial homeostasis is disrupted, or in a case wherein the intestinal barrier function is defective, an altered composition of gut-derived products reaches the liver via portal vein where, potentially, they could induce or exacerbate hepatic inflammation, eliciting complex responses in hepatic cells including cholangiocytes that became reactive undergoing proliferation, senescence, and apoptosis. Immune and mesenchymal cell chemotaxis is also activated to repair damaged tissue and remodel the biliary tree [32,33]. In recent years, several studies on animal models have been conducted regarding the role played by the intestinal microbiota on chronic biliary inflammation [34,35,39,40]. As well as this, many studies have shown that bile duct ligation causes bacterial overgrowth with increased bacterial translocation [36,37,41]. In fact, cholangiopathies, which alter the composition or the normal flow of the bile, may interfere with all of the processes involving the gut and the liver, ultimately causing dysbiosis and an increased or qualitatively altered PAMP/DAMP delivery to the liver via the portal circulation. The chemical composition of the bile and physical properties are modulated in pathological conditions affecting the intestine, the liver, the cholangiocyte, and even in systemic metabolic conditions, obesity, or systemic inflammation [36,37,41]. Bile products (e.g., oxysterols) affect per se the biliary barrier and DAMPs and PAMPs from bile can recirculate to the liver via the peribiliary plexus, the anatomical vasculature framework underlining the biliary–liver axis [36,37,41].

5. PBC

PBC is a chronic autoimmune cholestatic liver disease characterized by cholestasis, serologic reactivity to antimitochondrial antibodies (AMA) or a specific antinuclear antibody (gp210 and sp100 antibody) reactivity, and it is histologically characterized by a chronic non-suppurative inflammation of the interlobular bile ducts (parenchymal ducts). In recent years, numerous studies have focused their attention on potential links between the gut microbiome and PBC. Thanks to this research, a different composition of the microbiota was observed in patients affected by this pathology, both in the gut and in the bile (see Tables 1 and 2, respectively).

In PBC, the alteration of the gut microbiome may be involved in the onset, progression, and prognosis.

At pathobiology level, it has been proposed that AMAs, which bind to the mitochondrial E2 subunit of the pyruvate dehydrogenase complex (PDC-E2), may cross-react with bacterial proteins of *Escherichia coli*, *Lactobacillus delbrueckii*, and *Novosphingobium aromaticivorans* [42]. Indeed, the infection with *Novosphingobium aromaticivorans* of genetically susceptible mouse strains induces anti-PDC E2 responses and hepatic lesions similar to the typical lesions of human PBC. In the study Kitahata et al. [43] conducted in 34 patients with PBC and 21 healthy controls, the potential impact of the small intestinal mucosa-associated microbiota (MAM) in the pathogenesis of PBC was investigated. They performed 16S ribosomal RNA gene sequencing of MAM samples, obtained from the mucosa of the terminal ileum, and examined the relationship between the abundance of ileal MAM and chronic nonsuppurative destructive cholangitis. They concluded that dysbiosis of ileal MAM in PBC patients is characterized by an overgrowth of Sphingomon-

adaceae and *Pseudomonas*. Moreover, the abundance of Sphingomonadaceae is associated with chronic nonsuppurative destructive cholangitis in PBC, with a possible impact in the development of this disease.

Another demonstration regarding the alteration of the gut microbiota and bacterial translocation associated with immune pathology was given by Hong-Di et al. in a murine model of PBC, dn Transforming growth factor-beta receptor II (dnTGF β RII) mice [44]. The authors demonstrated that the administration of antibiotics and the consequent alteration of microbiota, significantly alleviates T-cell-mediated infiltration and bile duct damage. Instead, the Toll-like receptor 2 (TLR2)-deficient dnTGF β RII mice showed exacerbation of autoimmune cholangitis when their epithelial barrier integrity was disrupted for a downregulated expression of tight junction-associated protein ZO-1, leading to increased gut permeability and bacterial translocation. Regarding the pathogenesis of PBC, Liwinski T et al. [45], in their recent review, underline that several large-scale, case-control studies indicate a significantly higher prevalence of recurrent urinary tract infections in patients with PBC, mainly caused by *Escherichia coli* that seems to be involved in the production of the disease-specific AMA (Table 1). Another candidate involved in the pathogenesis of PBC, according to Selmi et al., is the ubiquitous bacterium *Novosphingobium aromaticivoran*, which causes a potential break in tolerance to the self E2 component of the mitochondrial pyruvate dehydrogenase complex (PDC-E2) through two independent mechanisms [46]. Lv et al. confirmed the presence of an altered microbiota in PBC patients. This depleted some potentially beneficial bacteria, such as *Ruminococcus bromii*, and enriched potentially entailing pathogens such as phylum *Proteobacteria*, family *Enterobacteriaceae*, and the genera *Veillonella*, *Streptococcus*, and *Klebsiella* [47]. Additionally, in a study conducted by Tang et al., a large Chinese cohort of treatment-naïve PBC patients demonstrated a significant reduction of within-individual microbial diversity and an increase of potential pathogens, such as *Klebsiella*, *Haemophilus*, *Streptococcus*, and *Veillonella* in ursodeoxycholic acid (UDCA)-naïve PBC patients compared to controls with a restoration of balance after 6 months of treatment with UDCA [48].

Furukawa et al. focused their attention on a possible correlation between the response to UDCA, first-line therapy of PBC, and gut microbiome composition. They demonstrated that, in PBC patients treated with UDCA, persistence of gut dysbiosis could affect their clinical prognosis. When compared with healthy subjects, these patients had a decreased abundance of the order *Clostridiales* and increased abundance of *Lactobacillales*. The UDCA non-responder group had a significantly lower population of the genus *Faecalibacterium*, known as butyrate-producing beneficial bacteria, and this might predict the long-term prognosis of patients with PBC [49]. Another interesting aspect is represented by the effect of the bile acid sequestrant on icteric PBC subjects, as Cholestyramine, used to treat cholestatic pruritus. [50]. In their study, Bo Li et al. demonstrate how the administration of cholestyramine caused beneficial responses which were closely related with compositional and functional alterations in gut commensal. In fact, gut microbial co-abundance networks showed distinct taxa interactions between subjects with superior remission (SR) and those with inferior remission (IR) at baseline. After treatment, compositional shifts of the microbiome in the SR group are characterized by the enrichment of two Lachnospiraceae species, typically producing short-chain fatty acids (SCFAs), as confirmed by metabolome analysis [50].

Second-line therapy of PBC is currently represented by obeticholic acid (OCA), a first-order agonist that selectively binds to FXR, involved in the modulation of hepatic inflammation, fibrosis, metabolic pathways, and regeneration [51]. OCA acts directly and indirectly to suppress bile acid production in the liver and increase bile flow, with a consequent reduced exposure to toxic levels of bile acids. In mice with Bile Duct Ligation, FXR raised the expression of genes involved in enteroprotection and impeded bacterial overgrowth and mucosal injury in ileum. In addition, FXR activation via OCA represses chemically-induced intestinal inflammation in mice, suggesting the possible role of FXR in inflammatory bowel disease [52].

As far as the biliary microbiota is concerned, in a study, Hiramatsu et al. analyzed gallbladder bile samples from patients with PBC, PSC, hepatitis virus C-related liver cirrhosis choledocholithiasis, and normal adult gallbladders. They noted that, in patients with PBC, 75% (~0.0001) of 100 clones were identified as so-called Gram-positive cocci, while these cocci were positive in only 5% of cholecystolithiasis. Hence, this supports the hypothesis that Gram-positive bacteria may be involved in the etiopathogenesis of PBC, triggering bile duct inflammation, and/or antigen presentation [53] (Table 2).

Table 1. Changes in gut microbiota in cholangiopathies.

	Overrepresented	Decreased Abundance
Primary Biliary Cholangitis		Acidobacteria [47]
	<i>γ</i> Proteobacteria []	
	Veillonella [45,47,48] Lactobacillales [49]	Clostridiales [49]
	Sphingomonadaceae [43,47] Pseudomonadaceae [43] Metylobacteriaceae [43] Moraxellaceae [47,48] Enterobacteriaceae [47,48] Neisseriaceae [47]	
	Haemophilus [45] Sterptococcus [45,47] Klebsiella [45,47,48] Actinobacillus [47]	Faecalimbacterium [48] Sutterella [48] Oscillospira [48]
	Anaeroglobus germinatus [47] Eterobacter asburiae [47] Hemophilus parainfluenzae [47] Megasphaera micronuciformis [47] Paraprevotella Clara [47] Pleuropneumoniae [47]	Lachnobacterium sp. [47]. Bacteroides eggerthii [47,48] Ruminococcus bromii [45,47]
Primary Sclerosing Cholangitis	Veillonella [54,55]	
	Clostridium [54] Escherichia [54] Streptococcus [45,55] Enterococcus [45,55]	Eubacterium spp. [54]
	Clostridium cluster XIVa [55] B. producta [55]	Ruminococcus Obeum [54] Bacterioides thetaiotaomicron [55] Faecalibacterium prausnitzii [55]
CCA	Bacterioidetes [56,57]	Firmicutes [56]
	Veillonella [56]	
	Muribaculaceae [57]	
	Streptococcus [56] Klebsiella [56] Muribaculum [57] Alistipes [57]	

Table 1. Taxonomy of gut microbiota in cholangiopathies. Legend: PHYLUM ORDER GENUS CLASS FAMILY SPECIES.

Table 2. Changes in biliary microbiota in cholestatic liver diseases.

	Overrepresented	Decreased Abundance
Primary Biliary Cholangitis	Corynebacterium otitidis [53]	
	Staphylococcus aureus [53] Enterococcus faecium [53] Streptococcus pneumoniae or other streptococci [53] Lactohacillus plantarum [53] Helicobacter pylori [53] Propionibacterium acnes [53] Lactobacillus gasseri [53] Agrobacterium tumefaciens [53] Flavobacterium breve [53] Clostridium sordellii [53] Micrococcus luteus [53]	

Table 2. Cont.

	Overrepresented	Decreased Abundance
Primary Sclerosing Cholangitis	<i>Enterococci</i> [58] <i>Candida</i> [59]	
	<i>Enterococcus Faecalis</i> [58,60]	
Primary Biliary Cholangitis	<i>Bacteroidetes</i> [61] <i>Acidobacteria</i> [62] <i>Planctomycetes</i> [62]	<i>Firmicutes</i> [61]
	<i>Methylophilaceae</i> [62]	
pCCA/dCCA	<i>Fusobacterium</i> [62] <i>Actinomyces</i> [62] <i>Novosphingobium</i> [62] <i>Enterococcus</i> [61] <i>Streptococcus</i> [61] <i>Klebsiella</i> [61] <i>Pyramidobacter</i> [61] <i>Geobacillus</i> [61] <i>Meiothermus</i> [61] <i>Anoxybacillus</i> [61]	<i>Nesterenkonia</i> [62] <i>Mesorhizobium</i> [62] <i>Rothia</i> [62]
	<i>Helicobacter Pylori</i> [62,63] <i>Prevotella</i> [62] <i>Helicobacter Bilis</i> [64]	

Table 2. Taxonomy of biliary microbiota in cholangiopathies. Legend: ■ PHYLUM ■ ORDER ■ GENUS ■ CLASS ■ FAMILY ■ SPECIES.

6. PSC

PSC is a cholangiopathy characterized by chronic fibroinflammatory damage of the large and extrahepatic bile ducts and is frequently associated with inflammatory bowel disease (IBD) [65]. Multiple simultaneous mechanisms appear to lead to PSC and its progression. One of these suggests that IBD may drive PSC rather than this being an epiphenomenon. Several lines of evidence propose a role for gut dysbiosis in the pathogenesis of PSC. The most accredited hypothesis proposes that a combination of environmental and genetic risk factors may induce biliary dysbiosis by rupturing the biliary mucosal barrier and generating toxic bile acid, which triggers bile duct fibrosis and cholangiocarcinogenesis. Dean et al. underline that abnormal enteric microbiome of PSC patients may promote the production of toxic products that are able to stimulate the immune-mediated damage of hepatocytes and the biliary tree by the migration of bacteria or associated toxins to the liver through the portal circulation [66]. Compared with IBD populations, PSC is characterized by a specific dysbiosis, but the difference between only PSC and PSC associated with IBD appears to be marginal, indicating that liver pathology is the principal corollary of microbial dysbiosis. In particular, in all of the studies we scrutinized, the genus *Veillonella* was enriched in the stool of PSC patients (Table 1). Other genera which frequently increase include: *Enterococcus*, *Streptococcus*, and *Lactobacillus*. Moreover, short-chain fatty acids producing anaerobes such as *Faecalibacterium* and *Coprococcus* were often found to be depleted in PSC patients [45]. Kummen et al., in a population of 136 patients with PSC (58% with IBD), 158 controls, and 93 patients with IBD without PSC, analyzed fecal DNA. The authors concluded that patients with PSC exhibited an increased prevalence of *Clostridium* species a depletion of *Eubacterium* spp and *Ruminococcus obeum*, an abundance of genes related to vitamin B6 synthesis and branched-chain amino acid synthesis, and reduced concentrations of vitamin B6 and branched-chain amino acids strongly associated with reduced liver transplantation-free survival [54]. Additionally, the salivary microbial signature of PSC is significantly altered, as demonstrated by Lapidot Y. et al., regardless of concomitant IBD, and includes 19 significantly altered species, of which eight species were consistently overrepresented in both fecal and saliva, as *Veillonella*, *Scardovia* and *Streptococcus*, and a sig-

nificant overrepresentation of *Clostridium cluster XIVa* and *B. producta* in the gut microbiome could be observed [55] (Table 1). In experimental animal models, Nakamoto et al. identify a subset of microorganisms associated with PSC/UC as central mediators of bacterial translocation, immune regulation, and disease progression. In fact, their study showed that hepatic TH17 primed cells were observed only in PSC/UC mice, and that they exhibit an increased expression of hepatic inflammatory markers [67]. The authors also identified three species: *Klebsiella pneumoniae*, *Proteus mirabilis*, and *Enterococcus gallinarum*. The colonization of mice with *Klebsiella P.* might promote bacterial translocation via intestinal epithelial cell barrier dysfunction. However, its underlying mechanism remains unknown. To try to explain how the gut microbiota and the gut–liver axis are implicated in PSC pathogenesis, Liao et al. demonstrated in a *Mdr2*^{−/−} mouse model that the loss of the phospholipid transporter *Mdr2* triggers a cholestatic response, which induces intrahepatic sclerosing cholangitis. By analysis of *Mdr2*^{−/−} microbiota, they demonstrated a reduced species diversity and significant alterations in the family of *Lachnospiraceae*, which have the important ability to form secondary bile acids and an increased activation of the NLRP3 inflammasome in dysbiotic *Mdr2*^{−/−} mice with consequent disruption of intestinal barrier integrity and translocation of endotoxin into the portal vein [68].

A possible therapeutic approach for this pathology is represented by using antibiotics that are capable of removing harmful microorganisms and replenishing beneficial microbes or metabolites. Among the antibiotics studied, vancomycin, a glycopeptide antibiotic with Gram-positive activity, showed more efficacy data associated with the dihydroxylation of primary bile acids into secondary bile acids [69]. However, vancomycin is highly hydrophobic and toxic. Excessive concentrations of vancomycin have been linked to inflammation, cholestasis, and carcinogenesis. To determine whether antibiotic treatment modulates liver immune responses, Nakamoto et al., in their study previously cited, treated PSC/UC mice with either metronidazole or vancomycin that have antibacterial properties against *K. pneumoniae* and *E. gallinarum*, respectively. These PSC/UC mice showed a robust TH17 hepatic immune response that was significantly reduced with the use of either antibiotic. *K. pneumoniae* should not be affected by vancomycin, so the decrease in TH17 in vancomycin-treated mice suggested the presence of additional pore-forming microbes targeted by vancomycin [67]. Tan LZ et al. describe their experience in treating 70 children affected by PSC and Ulcerative Colitis. In these patients the colitis of PSC–UC or autoimmune sclerosing cholangitis–ulcerative colitis (ASC–UC) can be severe and resistant to conventional therapy. Active colitis is a major risk factor for recurrent liver disease and graft failure. The authors concluded that oral vancomycin demonstrated excellent efficacy with regards to achieving clinical, biomarker, mucosal and histological remission of colitis in children with ASC and PSC [70]. Another recent report, published by Britto SL et al., underlined the abundance changes in *Fusobacterium*, *Haemophilus*, and *Neisseria* on longitudinal salivary and fecal microbiome changes in a pediatric PSC–UC patient over the first 90 days of vancomycin therapy [71]. In a systematic review and meta-analysis, Shah A. et al. evaluated the effect of antibiotic therapy in PSC patients. A total of 124 PSC patients received antibiotic therapy (57 treated with metronidazole, 35 with vancomycin, 16 each with rifaximin and minocycline). Treatment with antibiotics in PSC patients was associated with a statistically significant reduction in ALP, Mayo Risk Score, and total serum bilirubin level. Particularly ALP reduction was greatest for vancomycin and smallest with metronidazole, without significant adverse effects [72]. Other interesting antibiotics are rifaximin and minocycline. Rifaximin had no effect in decreasing cholestatic markers and the Mayo score in 16 PSC patients, as demonstrated by Tabibian et al. [73]. In contrast, minocycline was shown to cause an improvement in ALP levels and the Mayo score in 16 patients. Fecal Microbiome Transplantation (FMT) is a promising treatment for PSC patients. In one small pilot study, patients with PSC underwent FMT, and three of them experienced a $\geq 50\%$ decrease in ALP levels. Its effect may be correlated with bacterial diversity and donor engraftment. The species that correlated with decreased ALP levels

were Erysipelotrichaceae, Paraprevotella, Bacteroides and Alistipes taxa. Further studies are needed to establish the efficacy and safety of these therapies.

Statin use is associated with improved outcomes of patients with PSC [74]. The rationale for this finding and for a current RCT with statins in PSC could be the fact that statin therapy is associated with a lower prevalence of gut microbiota dysbiosis [75].

As far as the biliary microbiome is concerned, Zigmond E et al. demonstrated, in a cohort of 189 patients affected by PSC undergoing endoscopic retrograde cholangiopancreatography (ERCP) for bile fluid collection, the presence of *Enterococci* that conferred risk of disease progression, such as fungobilia [58]. Additionally, Liwinsky et al. observed that the bile fluid of PSC patients was enriched by the presence of *Enterococcus faecalis*, a potentially pathogenic bacterium (Table 2) involved in an increase of the bile acid, tauroolithocholic acid, which is known to be pro-inflammatory and potentially carcinogenic [60]. They also found that the disease duration is associated with an increased microbial burden, especially *Fusobacterium* and *Gemella*, which are associated with CCA development. *Fusobacteria* were increased during the long-term course of PSC. Miyabe et al. found that *Fusobacterium nucleatum* was statistically associated with PSC. However, in this study, statistical significance was not reached for IBD, obesity, or choledocholithiasis, according to their correlation analysis between the *Fusobacterium* level and these variables [76].

In a prospective non-randomized trial, *Candida* was detected in the bile of 7 out of 49 PSC patients with dominant stenosis. The authors also concluded that biliary *Candida* was associated with more severe cholangitis [59] (Table 2).

7. CCA

In recent years, the term “oncobiome” has been introduced to indicate the implication of gut microbiota in the development of neoplastic diseases [77]. To date, the most probable hypotheses through which the microbiome influences cancer development are related to the modulation of host local and systemic immune responses by the microbiota [78], the role of bacterial toxins on carcinogenesis [79], and modifications in microbial and host metabolism [80].

CCA is a malignant tumor that originates from the epithelial cells of the PBGs [81]. It accounts for 3% of gastrointestinal cancers, although it is considered a rare tumor [82]. The incidence is lowest in Eastern countries, where the number of cases is less than 5/100,000 people/year. [83] However, the burden of CCA is underestimated worldwide as it is the leading cause of metastasis of unknown origin [84]. Surgery is the only potentially curative strategy for CCA. In advanced forms, 5-year survival is lower than 15% [83]. From an anatomic point of view, CCA can be classified into intrahepatic (iCCA), peribiliary (pCCA), and distal (dCCA). This classification reflects a histological differentiation as pCCAs and dCCAs are more frequently mucinous adenocarcinomas, unlike iCCAs [81]. Different epidemiological studies highlight that the several risk factors implicated in cholangiocarcinogenesis are different between iCCA and the others [85]. Established risk factors for CCA are parasitic infections, biliary tract diseases (such as primary sclerosing cholangitis (PSC) and Caroli disease), and hepatolithiasis. Other risk factors are liver cirrhosis, hepatitis B, hepatitis C, diabetes mellitus, obesity, alcohol, and smoking [83]. CCA may develop through the accumulation of epigenetic modifications that occur due to exposure to environmental and microbial factors. The biliary ducts are vulnerable to the gut microbiome by way of the gut–liver axis [15] and, as for other tumors, on top of the already known risk factors, recent experimental studies have shown that intestinal microbial dysbiosis may also be involved in the development of CCA [62,86,87] (Table 2). This is probably related to the pathway of bile acid metabolism.

Recently, some studies have highlighted that CCA has a different gut microbiome, even compared to the other primary liver tumor, the hepatocellular carcinoma. The study conducted by Deng et al. showed that patients with CCA had a higher α -diversity than hepatocellular carcinoma (HCC) patients, while HCC patients had decreased α -diversity in comparison to controls. This presented the opportunity to use the gut microbiome as

a diagnostic instrument in liver cancer [56]. In another study, Zhang et al. studied the discrepancy in gut microbiota between CCA patients, patients with cholelithiasis, and healthy patients (Table 1). CCA patients and healthy patients had a more species-rich and homogeneous microbiota than the cholelithiasis group, while there were differences in α -diversity between healthy controls and CCA patients [57]. Jia et al. have recently shown that the gut microbiome is closely related to the tumorigenesis and progression of CCA; furthermore, the intestinal microbiome of the patients affected by iCCA had the highest diversity [88] (Table 1).

In comparison with other categories, at the genus level, *Alloscardovia*, *Peptostreptococcaceae*, *Actinomyces*, and *Lactobacillus* were remarkably increased in the patients affected by iCC. Furthermore, differences in the tissue microbiome were found in liver fluke-associated CCA and non-liver fluke-associated CCA [89]. In this regard, it is known that *Opisthorchis Viverrini* infection is a risk factor for CCA. Studies highlighted that this infection is responsible for modifying the gut microbiota. In particular, in these patients, it has been marked with an increase of *Helicobacter* spp. in stool samples and an overexpression of two genes, Cag A and Cag, which are implicated in promoting inflammation and fibrosis of the bile ducts [90].

Regarding the various species of *Helicobacter pylori*, the most significant studies include two meta-analyses and three prospective studies. The two meta-analyses examine ten case-control studies. Both of these analyses expose a significant relationship between *Helicobacter* species and the presence of CCA compared with control patients with benign diseases of the biliary tract or without pathologies [63,91]. Furthermore, these analyses highlighted an increased rate of *H. pylori* (49.5% vs. 33.3%, $p = 0.003$) and *H. bilis* (52.2% vs. 23.7%, $p < 0.0001$) in patients affected by CCA compared to those affected by benign biliary diseases [62]. The three prospective studies confirm the association between *Helicobacter* species and CCA, as already shown by the meta-analyses [62,64,92].

Other studies investigated the possible association between CCA and microbiota. There are fourteen significant studies [93]. Different sample types from patients with BTC were analyzed: bile, fecal, plasma, and tissue samples. Microbiota was analyzed through an automated microbiology system (Phoenix or Vitek-2), 16S rRNA gene sequencing or shotgun metagenomics. The stage of CCA was not mentioned in most of the studies. These studies report an increase in *Fusobacteria* (four studies), *Enterobacteriaceae* (three studies), and *Pseudomonadaceae* (three studies) in patients with biliary tract cancer (CCA and gallbladder carcinoma), HCC, and pancreatic head tumors [93].

At the same time, a great amount of evidence hints that the bile microbiota plays a fundamental role in diseases of the biliary tract, including CCA (Table 2). Avilés reported that, for the first time, the microbiota in the biliary tract in cancer and non-cancer conditions found a significant increase in the genera *Novosphingobium*, *Actinomyces*, *Fusobacterium* and *Prevotella*, and a decrease in *Nesterenkonia* and *Rothia* in ECCA [56]. In a recent study, Saab et al., have described the biliary microbiota in extrahepatic CCA (eCCA) patients and compared them with controls. They identified a dysbiosis that was significantly related to eCCA. This included genera such as *Bacteroides*, *Geobacillus*, *Anoxybacillus*, and *Meiothermus*, which were found to be more abundant in cases than in controls [61]. Even Miyabe et al. have recently found significant differences in the bile microbiome in PSC and CCA. Specifically, it was observed that long-lasting PSC increase the amount of bile microbioma associated with an increase in specific bile microbioma characteristics. This may increase inflammation in the biliary tract and influence the risk of CCA in patients with PSC [76]. Aside from those previously mentioned, several other studies have investigated the association between CCA and specific micro-organisms [76].

8. Conclusions

In recent years, in addition to the concept of gut microbiota referring to pathogenic bacteria and other microorganisms that colonize the gastrointestinal tract, several discoveries have been made regarding the biliary microbiome and the close communication

between these two environments, their condition of balance through the enterohepatic circulation, and the state of immune tolerance. Under conditions of altered equilibrium, bacterial products deriving from the intestine induce the activation of strong immune responses in cholangiocytes which may contribute to the development of biliary lesions. At the same time, other studies are gradually delineating a specific composition of the gut and biliary microbiota in patients with cholangiopathies that could be partly responsible for the activation of cholangiocytes. Advances in the knowledge and understanding of the gut–liver axis and biliary–liver axis are of fundamental importance because they are driving the development of diagnostic, prognostic, and therapeutic tools based on microbiota to manage cholangiopathies, such as FXR agonists and antibiotics.

Funding: The research leading to these results has received funding from MUR under PNRR M4C2I1.3 Heal Italia project PE00000019 CUP Sapienza University of Rome to Domenico Alvaro.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Zeuzem, S. Gut-liver axis. *Int. J. Color. Dis.* **2000**, *15*, 59–82. [[CrossRef](#)]
2. Tilg, H.; Cani, P.D.; Mayer, E.A. Gut microbiome and liver diseases. *Gut* **2016**, *65*, 2035–2344. [[CrossRef](#)]
3. Okumura, R.; Takeda, K. Maintenance of intestinal homeostasis by mucosal barriers. *Inflamm. Regen.* **2018**, *38*, 5. [[CrossRef](#)] [[PubMed](#)]
4. Nicoletti, A.; Ponziani, F.R.; Biolato, M.; Valenza, V.; Marrone, G.; Sganga, G.; Gasbarrini, A.; Miele, L.; Grieco, A. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. *World J. Gastroenterol. WJG* **2019**, *25*, 4814–4834. [[CrossRef](#)]
5. Meyer-Hoffert, U.; Hornef, M.W.; Henriques-Normark, B.; Axelsson, L.G.; Midtvedt, T.; Putsep, K.; Andersson, M. Secreted enteric antimicrobial activity localizes to the mucus surface layer. *Gut* **2008**, *57*, 764–771. [[CrossRef](#)]
6. Marchesi, J.R.; Ravel, J. The vocabulary of microbiome research: A proposal. *Microbiome* **2015**, *30*, 31. [[CrossRef](#)]
7. Rinninella, E.; Raoul, P.; Cintoni, M.; Franceschi, F.; Miggiano, G.A.D.; Gasbarrini, A.; Mele, M.C. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. *Microorganisms* **2019**, *7*, 14. [[CrossRef](#)]
8. Stecher, B.; Maier, L.; Hardt, W.D. Blooming' in the gut: How dysbiosis might contribute to pathogen evolution. *Nat. Rev. Microbiol.* **2013**, *11*, 277–284. [[CrossRef](#)]
9. Turner, J.R. Intestinal mucosal barrier function in health and disease. *Nat. Rev. Immunol.* **2009**, *9*, 799–809. [[CrossRef](#)] [[PubMed](#)]
10. Ran, Y.; Fukui, H.; Xu, X.; Wang, X.; Ebisutani, N.; Tanaka, Y.; Maeda, A.; Makizaki, Y.; Ohno, H.; Kondo, T.; et al. Alteration of Colonic Mucosal Permeability during Antibiotic-Induced Dysbiosis. *Int. J. Mol. Sci.* **2020**, *21*, 6108. [[CrossRef](#)] [[PubMed](#)]
11. Tajeddin, E.; Sherafat, S.J.; Majidi, M.R.S.; Alebouyeh, M.; Alizadeh, A.H.M.; Zali, M.R. Association of diverse bacterial communities in human bile samples with biliary tract disorders: A survey using culture and polymerase chain reaction-denaturing gradient gel electrophoresis methods. *Eur. J. Clin. Microbiol. Infect. Dis.* **2016**, *35*, 1331–1339. [[CrossRef](#)]
12. Molinero, N.; Ruiz, L.; Milani, C.; Gutiérrez-Díaz, I.; Sánchez, B.; Mangifesta, M.; Segura, J.; Cambero, I.; Campelo, A.B.; García-Bernardo, C.M.; et al. The human gallbladder microbiome is related to the physiological state and the biliary metabolic profile. *Microbiome* **2019**, *7*, 100. [[CrossRef](#)]
13. Serra, N.; Di Carlo, P.; D'Arpa, F.; Battaglia, E.; Fasciana, T.; Gulotta, G.; Maida, C.M.; Rodolico, V.; Giammanco, A.; Sergi, C. Human bile microbiota: A retrospective study focusing on age and gender. *J. Infect. Public Health* **2021**, *14*, 206–213. [[CrossRef](#)]
14. Verdier, J.; Luedde, T.; Sellge, G. Biliary Mucosal Barrier and Microbiome. *Visc. Med.* **2015**, *31*, 156–161. [[CrossRef](#)]
15. Tripathi, A.; Debelius, J.; Brenner, D.A.; Karin, M.; Loomba, R.; Schnabl, B.; Knight, R. The gut–liver axis and the intersection with the microbiome. *Nat. Rev. Gastroenterol. Hepatol.* **2018**, *15*, 397–411. [[CrossRef](#)]
16. Gäbele, E.; Mühlbauer, M.; Dorn, C.; Weiss, T.S.; Froh, M.; Schnabl, B.; Wiest, R.; Schölmerich, J.; Obermeier, F.; Hellerbrand, C. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. *Biochem. Biophys. Res. Commun.* **2008**, *376*, 271–276. [[CrossRef](#)]
17. Cardinale, V.; Wang, Y.; Carpino, G.; Alvaro, D.; Reid, L.M.; Gaudio, E. Multipotent stem cells in the biliary tree. *Ital. J. Anat Embryol.* **2010**, *115*, 85–90.
18. Carpino, G.; Cardinale, V.; Onori, P.; Franchitto, A.; Berloco, P.B.; Rossi, M.; Wang, Y.; Semeraro, R.; Anceschi, M.; Brunelli, R.; et al. Biliary tree stem/progenitor cells in glands of extrahepatic and intrahepatic bile ducts: An anatomical in situ study yielding evidence of maturational lineages. *J. Anat.* **2012**, *2*, 186–199. [[CrossRef](#)]

19. Cardinale, V.; Wang, Y.; Carpino, G.; Mendel, G.; Alpini, G.; Gaudio, E.; Reid, L.M.; Alvaro, D. The biliary tree a reservoir of multipotent stem cells. *Nat. Rev. Gastroenterol. Hepatol.* **2012**, *28*, 231–240. [[CrossRef](#)]
20. Tabibian, J.H.; O'Hara, S.P.; Trussoni, C.E.; Tietz, P.S.; Splinter, P.L.; Mounajjed, T.; Hagey, L.R.; LaRusso, N.F. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. *Hepatology* **2016**, *63*, 185–196. [[CrossRef](#)]
21. Lefebvre, P.; Cariou, B.; Lien, F.; Kuipers, F.; Staels, B. Role of bile acids and bile acid receptors in metabolic regulation. *Physiol. Rev.* **2009**, *89*, 147–191. [[CrossRef](#)]
22. Makishima, M.; Okamoto, A.Y.; Repa, J.J.; Tu, H.; Learned, R.M.; Luk, A.; Shan, B. Identification of a nuclear receptor for bile acids. *Science* **1999**, *284*, 1362–1365. [[CrossRef](#)]
23. Kawamata, Y.; Fujii, R.; Hosoya, M.; Harada, M.; Yoshida, H.; Miwa, M.; Fukusumi, S.; Habata, Y.; Itoh, T.; Shintani, Y.; et al. A G protein-coupled receptor responsive to bile acids. *J. Biol. Chem.* **2003**, *278*, 9435–9440. [[CrossRef](#)]
24. Finn, P.D.; Rodriguez, D.; Kohler, J.; Jiang, Z.; Wan, S.; Blanco, E.; King, A.J.; Chen, T.; Bell, N.; Dragoli, D. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2019**, *316*, 412–424. [[CrossRef](#)]
25. Fiorucci, S.; Mencarelli, A.; Palladino, G.; Cipriani, S. Bile-acid-activated receptors: Targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. *Trends Pharmacol. Sci.* **2009**, *30*, 570–580. [[CrossRef](#)]
26. Iracheta-Vellve, A.; Calenda, C.D.; Petrasek, J.; Ambade, A.; Kodys, K.; Adorini, L.; Szabo, G. FXR and TGR5 agonists ameliorate liver injury, steatosis, and inflammation after binge or prolonged alcohol feeding in mice. *Hepatol. Commun.* **2018**, *2*, 1379–1391. [[CrossRef](#)]
27. Mertens, K.L.; Kalsbeek, A.; Soeters, M.R.; Eggink, H.M. Bile acid signaling pathways from the enterohepatic circulation to the central nervous system. *Front. Neurosci.* **2017**, *11*, 617. [[CrossRef](#)]
28. Wahlstrom, A.; Sayin, S.I.; Marschall, H.U.; Backhed, F. Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. *Cell Metab.* **2016**, *24*, 41–50. [[CrossRef](#)]
29. Stärkel, P.; Schnabl, B. Bidirectional Communication between Liver and Gut during Alcoholic Liver Disease. *Semin. Liver Dis.* **2016**, *36*, 331–339. [[CrossRef](#)]
30. De Aguiar Vallim, T.Q.; Tarling, E.J.; Edwards, P.A. Pleiotropic roles of bile acids in metabolism. *Cell Metab.* **2013**, *17*, 657–669. [[CrossRef](#)]
31. Sayin, S.I.; Wahlstrom, A.; Felin, J.; Jantti, S.; Marschall, H.U.; Bamberg, K.; Bäckhed, F. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. *Cell Metab.* **2013**, *17*, 225–235. [[CrossRef](#)]
32. Alvaro, D.; Bragazzi, M.C.; Ridola, L. Inflammatory and neoplastic cholangioapthies. *Recenti. Prog. Med.* **2018**, *109*, 595–599. [[PubMed](#)]
33. Franchitto, A.; Onori, P.; Renzi, A.; Carpino, G.; Mancinelli, R.; Alvaro, D.; Gaudio, E. Recent advances on the mechanisms regulating cholangiocyte proliferation and the significance of the neuroendocrine regulation of cholangiocyte pathophysiology. *Ann. Transl. Med.* **2013**, *1*, 27. [[PubMed](#)]
34. Schruppf, E.; Kummen, M.; Valestrand, L.; Greiner, T.U.; Holm, K.; Arulampalam, V.; Reims, H.M.; Baines, J.; Bäckhed, F.; Karlsen, T.H.; et al. The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation. *J. Hepatol.* **2017**, *66*, 382–389. [[CrossRef](#)] [[PubMed](#)]
35. Lichtman, S.N.; Wang, J.; Clark, R.L. A microcholangiographic study of liver disease models in rats. *Acad. Radiol.* **1995**, *2*, 515–521. [[CrossRef](#)]
36. Fouts, D.E.; Torralba, M.; Nelson, K.E.; Brenner, D.A.; Schnabl, B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. *J. Hepatol.* **2012**, *56*, 1283–1292. [[CrossRef](#)]
37. Ding, J.W.; Andersson, R.; Soltesz, V.; Willen, R.; Bengmark, S. The role of bile and bile acids in bacterial translocation in obstructive jaundice in rats. *Eur. Surg. Res.* **1993**, *25*, 11–19. [[CrossRef](#)]
38. Chiang, J.Y.L. Bile acid metabolism and signaling in liver disease and therapy. *Liver Res.* **2017**, *1*, 3–9. [[CrossRef](#)]
39. Maroni, L.; Haibo, B.; Ray, D.; Zhou, T.; Wan, Y.; Meng, F.; Marzioni, M.; Alpini, G. Functional and Structural Features of Cholangiocytes in Health and Disease. *Cell Mol. Gastroenterol. Hepatol.* **2015**, *1*, 368–380. [[CrossRef](#)]
40. Lichtman, S.N.; Okoruwa, E.E.; Keku, J.; Schwab, J.H.; Sartor, R.B. Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. *J. Clin. Investig.* **1992**, *90*, 1313–1322. [[CrossRef](#)]
41. Slocum, M.M.; Sittig, K.M.; Specian, R.D.; Deitch, E.A. Absence of intestinal bile promotes bacterial translocation. *Am. Surg.* **1992**, *58*, 305–310. [[PubMed](#)]
42. Mattner, J. Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC). *Int. J. Mol. Sci.* **2016**, *17*, 1864. [[CrossRef](#)] [[PubMed](#)]
43. Kitahata, S.; Yamamoto, Y.; Yoshida, O.; Tokumuto, Y.; Kawamura, T.; Furukuwa, S.; Kumagi, M.; Hirotska, M.; Takeshita, E.; Abe, M.; et al. Ileal mucosa-associated microbiota overgrowth associated with pathogenesis of primary biliary cholangitis. *Sci. Rep.* **2021**, *5*, 11. [[CrossRef](#)] [[PubMed](#)]
44. Ma, H.D.; Zhao, Z.B.; Ma, W.T.; Liu, Q.Z.; Gao, C.Y.; Li, L.; Wang, J.; Tsuneyama, K.; Liu, B.; Zhang, W.; et al. Gut microbiota translocation promotes autoimmune cholangitis. *J. Autoimmun.* **2018**, *95*, 47–57. [[CrossRef](#)]

45. Liwinski, T.; Heinemann, M.; Schramm, C. The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts. *Semin. Immunopathol.* **2022**, *44*, 485–507. [[CrossRef](#)]
46. Selmi, C.; Balkwill, D.L.; Invernizzi, P.; Ansari, A.A.; Coppel, R.L.; Podda, M.; Leung, P.S.; Kenny, T.P.; Van De Water, J.; Nantz, M.H.; et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. *Hepatology* **2003**, *38*, 1250–1257. [[CrossRef](#)]
47. Lv, L.-X.; Fang, D.-Q.; Shi, D.; Chen, D.Y.; Yan, R.; Zhu, Y.-X.; Chen, Y.-F.; Shao, L.; Guo, F.-F.; Wu, W.-R.; et al. Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis. *Environ. Microbiol.* **2016**, *18*, 2272–2286. [[CrossRef](#)]
48. Tang, R.; Wei, Y.; Li, Y.; Chen, W.; Chen, H.; Wang, Q.; Yang, F.; Miao, Q.; Xiao, X.; Zhang, H.; et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. *Gut* **2018**, *67*, 534–571. [[CrossRef](#)]
49. Furukawa, M.; Moriya, K.; Nakayama, J.; Inoue, T.; Momoda, R.; Kawaratani, H.; Namisaki, T.; Sato, S.; Douhara, A.; Kaji, K.; et al. Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. *Hepatol. Res.* **2020**, *50*, 840–852. [[CrossRef](#)]
50. Li, B.; Zhang, J.; Chen, Y.; Wang, Q.; Yan, L.; Wang, R.; Wei, Y.; You, Z.; Li, Y.; Miao, Q.; et al. Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary Cholangitis. *Gut Microbes.* **2021**, *13*, 1946366. [[CrossRef](#)]
51. Han, C.Y. Update on FXR Biology: Promising Therapeutic Target? *Int. J. Mol. Sci.* **2018**, *16*, 2069. [[CrossRef](#)] [[PubMed](#)]
52. Gadaleta, R.M.; Van Erpecum, K.J.; Oldenburg, B.; Willemsen, E.C.; Renooij, W.; Murzilli, S.; Klomp, L.W.; Siersema, P.D.; Schipper, M.E.; Danese, S.; et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. *Gut* **2011**, *60*, 463–472. [[CrossRef](#)] [[PubMed](#)]
53. Hiramatsu, K.; Harada, K.; Tsuneyama, K.; Sasaki, M.; Fujita, S.; Hashimoto, T.; Kaneko, S.; Kobayashi, K.; Nakanuma, Y. Amplification and sequence analysis of partial bacterial 16S ribosomal RNA gene in gallbladder bile from patients with primary biliary cirrhosis. *J. Hepatol.* **2000**, *33*, 9–18. [[CrossRef](#)] [[PubMed](#)]
54. Kummen, M.; Thingholm, L.B.; Rühlemann, M.C.; Holm, K.; Hansen, S.H.; Lucas Silva, L.M.; Liwinski, T.; Zenouzi, R.; Storm-Larsen, C.; Midttun, Ø.; et al. Altered gut microbial metabolism of essential nutrients in primary sclerosing cholangitis. *Gastroenterology* **2020**, *160*, 1784–1798. [[CrossRef](#)]
55. Lapidot, Y.; Amir, A.; Ben-Simon, S.; Veitsman, E.; Cohen-Ezra, O.; Davidov, Y.; Weiss, P.; Bradichevski, T.; Segev, S.; Koren, O.; et al. Alterations of the salivary and fecal microbiome in patients with primary sclerosing cholangitis. *Hepatol. Int.* **2021**, *15*, 191–201. [[CrossRef](#)]
56. Deng, T.; Li, J.; He, B.; Chen, B.; Liu, F.; Chen, Z.; Zheng, J.; Shi, Z.; Zhang, T.; Deng, L.; et al. Gut Microbiome Alteration as a Diagnostic Tool and Associated with Inflammatory Response Marker in Primary Liver Cancer. *Hepatol. Int.* **2022**, *16*, 99–111. [[CrossRef](#)]
57. Zhang, T.; Zhang, S.; Jin, C.; Lin, Z.; Deng, T.; Xie, X.; Deng, L.; Li, X.; Ma, J.; Ding, X.; et al. A Predictive Model Based on the Gut Microbiota Improves the Diagnostic Effect in Patients with Cholangiocarcinoma. *Front. Cell Infect. Microbiol.* **2021**, *11*, 751795. [[CrossRef](#)]
58. Zigmond, E.; Zecher, B.F.; Bartels, A.-L.; Baran, T.Z.; Rösch, T.; Schachschal, G.; Lohse, A.W.; Ehlken, H.; Schramm, C. Bile Duct Colonization with *Enterococcus* sp. Associates with Disease Progression in Primary Sclerosing Cholangitis. *Clin. Gastroenterol. Hepatol.* **2022**. [[CrossRef](#)]
59. Kulaksiz, H.; Rudolph, G.; Kloeters-Plachky, P.; Sauer, P.; Geiss, H.; Stiehl, A. Biliary candida infections in primary sclerosing cholangitis. *J. Hepatol.* **2006**, *45*, 711–716. [[CrossRef](#)]
60. Liwinski, T.; Zenouzi, R.; John, C.; Ehlken, H.; Rühlemann, M.C.; Bang, C.; Groth, S.; Lieb, W.; Kantowski, M.; Andersen, N.; et al. Alterations of the bile microbiome in primary sclerosing cholangitis. *Gut* **2020**, *69*, 665–672. [[CrossRef](#)]
61. Saab, M.; Mestivier, D.; Sohrabi, M.; Rodriguez, C.; Khonsari, M.R.; Faraji, A.; Sobhani, I. Characterization of biliary microbiota dysbiosis in extrahepatic cholangiocarcinoma. *PLoS ONE* **2021**, *9*, e0247798. [[CrossRef](#)] [[PubMed](#)]
62. Avilés-Jiménez, F.; Guitron, A.; Segura-López, F.; Méndez-Tenorio, A.; Iwai, S.; Hernández-Guerrero, A.; Torres, J. Microbiota studies in the bile duct strongly suggest a role for *Helicobacter pylori* in extrahepatic cholangiocarcinoma. *Clin. Microbiol. Infect.* **2016**, *22*, 178-e11–178-e22. [[CrossRef](#)] [[PubMed](#)]
63. Zhou, D.; Wang, J.D.; Weng, M.; Zhang, Y.; Wang, X.; Gong, W.; Quan, Z. Infections of *Helicobacter* spp. in the biliary system are associated with biliary tract cancer: A meta-analysis. *Eur. J. Gastroenterol. Hepatol.* **2013**, *25*, 447–454. [[CrossRef](#)] [[PubMed](#)]
64. Segura-López, F.K.; Avilés-Jiménez, F.; Güitrón-Cantú, A.; Valdéz-Salazar, H.A.; León-Carballo, S.; Guerrero-Pérez, L.; Fox, J.G.; Torres, J. Infection with *Helicobacter bilis* but not *Helicobacter hepaticus* was Associated with Extrahepatic Cholangiocarcinoma. *Helicobacter* **2015**, *20*, 223–230. [[CrossRef](#)]
65. Bowlus, C.L.; Arrivé, L.; Bergquist, A.; Deneau, M.; Forman, L.; Ilyas, S.I.; Lunsford, K.E.; Martinez, M.; Sapisochin, G.; Shroff, R.; et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. *Hepatology* **2023**, *77*, 659–702. [[CrossRef](#)]
66. Dean, G.; Hanauer, S.; Levitsky, J. The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications. *Hepatology* **2020**, *72*, 1127–1138. [[CrossRef](#)]

67. Nakamoto, N.; Sasaki, N.; Aoki, R.; Miyamoto, K.; Suda, W.; Teratani, T.; Suzuki, T.; Koda, Y.; Chu, P.-S.; Taniki, N.; et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. *Nat. Microbiol.* **2019**, *4*, 492–503. [[CrossRef](#)]
68. Liao, L.; Schneider, K.M.; Galvez, E.J.C.; Frissen, M.; Marschall, H.U.; Su, H.; Hatting, M.; Wahlström, A.; Haybaeck, J.; Puchas, P.; et al. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis. *Gut* **2019**, *68*, 1477–1492. [[CrossRef](#)]
69. Vrieze, A.; Out, C.; Fuentes, S.; Jonker, L.; Reuling, I.; Kootte, R.S.; Nood, E.V.; Holleman, F.; Knaapen, M.; Romijn, J.A.; et al. Impact of Oral Vancomycin on Gut Microbiota, Bile Acid Metabolism, and Insulin Sensitivity. *J. Hepatol.* **2014**, *72*, 1729–1738. [[CrossRef](#)]
70. Tan, L.Z.; Reilly, C.R.; Steward-Harrison, L.C.; Balouch, F.; Muir, R.; Lewindon, P.J. Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis. *Gut* **2019**, *68*, 1533–1535. [[CrossRef](#)]
71. Britto, S.L.; Hoffman, K.L.; Tessier, M.E.; Petrosino, J.; Miloh, T.; Kellermayer, R. Microbiome Responses to Vancomycin Treatment in a Child with Primary Sclerosing Cholangitis and Ulcerative Colitis. *ACG Case Rep. J.* **2021**, *11*, 8. [[CrossRef](#)] [[PubMed](#)]
72. Shah, A.; Crawford, D.; Burger, D.; Martin, N.; Walker, M.; Talley, N.J.; Tallis, C.; Jones, M.; Stuart, K.; Keely, A.; et al. Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: A systematic review and meta-analysis. *Semin. Liver Dis.* **2019**, *39*, 432–441. [[CrossRef](#)] [[PubMed](#)]
73. Tabibian, J.H.; Gossard, A.; El-Youssef, M.; Eaton, J.E.; Petz, J.; Jorgensen, R.; Enders, F.B.; Tabibian, A.; Lindor, K.D. Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis. *Am. J. Ther.* **2017**, *24*, 56–63. [[CrossRef](#)] [[PubMed](#)]
74. Stokkenad, K.; Hoijer, J.; Bottai, M.; Soderberg-Lofdal, K.; Bergquit, A. Statin use is associated with improved outcomes of patients with primary sclerosing cholangitis. *Clin. Gastroenterol. Hepatol.* **2019**, *17*, 1860–1866. [[CrossRef](#)] [[PubMed](#)]
75. Vieira-Silva, S.; Falony, G.; Balsa, E.; Nielsen, T.; Aron-Wisnewsky, J.; Chakaroun, R.; Forslund, S.K.; Assmann, K.; Valles-Colmer, M.; Nguyen, T.D.; et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. *Nature* **2020**, *581*, 310–315. [[CrossRef](#)] [[PubMed](#)]
76. Miyabe, K.; Chandrasekhara, V.; Wongjarupong, N.; Chen, J.; Yang, L.; Johnson, S.; Chia, N.; Walther-Antonio, M.; Yao, J.Z.; Harrington, S.C.; et al. Potential Role of Inflammation-Promoting Biliary Microbiome in Primary Sclerosing Cholangitis and Cholangiocarcinoma. *Cancers* **2022**, *24*, 2120. [[CrossRef](#)]
77. Thomas, R.M.; Jobin, C. The Microbiome and Cancer: Is the “Oncobiome” Mirage Real? *Trends Cancer* **2015**, *1*, 24–35. [[CrossRef](#)]
78. Yu, A.L.; Zhao, L.; Eaton, K.A.; Ho, S.; Chen, J.; Poe, S.; Becker, J.; Gonzalez, A.; McKinstry, D.; Hasso, M.; et al. Gut Microbiota Modulate CD8 T Cell Responses to Influence Colitis-Associated Tumorigenesis. *Cell Rep.* **2020**, *31*, 107471. [[CrossRef](#)]
79. Arthur, J.C.; Perez-Chanona, E.; Mühlbauer, M.; Tomkovich, S.; Uronis, J.M.; Fan, T.-J.; Campbell, B.J.; Abujamel, T.; Dogan, B.; Rogers, A.B.; et al. Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota. *Science* **2012**, *338*, 120–123. [[CrossRef](#)]
80. Ma, C.; Han, M.; Heinrich, B.; Fu, Q.; Zhang, Q.; Sandhu, M.; Agdashian, D.; Terabe, M.; Berzofsky, J.A.; Fako, V.; et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. *Science* **2018**, *25*, 360.
81. Vignone, A.; Biancanello, F.; Casadio, M.; Pesci, L.; Cardinale, V.; Ridola, L.; Alvaro, D. Emerging Therapies for Advanced Cholangiocarcinoma: An Updated Literature Review. *J. Clin. Med.* **2021**, *24*, 4901. [[CrossRef](#)] [[PubMed](#)]
82. Banales, J.M.; Marin, J.J.G.; Lamarca, A.; Rodrigues, P.M.; Khan, S.A.; Roberts, L.R.; Cardinale, V.; Carpino, G.; Andersen, J.B.; Braconi, C.; et al. Cholangiocarcinoma 2020: The next horizon in mechanisms and management. *Nat. Rev. Gastroenterol. Hepatol.* **2020**, *17*, 557–588. [[CrossRef](#)] [[PubMed](#)]
83. Khan, S.A.; Tavolari, S.; Brandi, G. Cholangiocarcinoma: Epidemiology and risk factors. *Liver Intern.* **2019**, *39*, 19–31. [[CrossRef](#)]
84. Varadhachary, G.R.; Raber, M.N. Cancer of unknown primary site. *N. Eng. J. Med.* **2014**, *8*, 757–765. [[CrossRef](#)]
85. Valle, J.W.; Kelley, R.K.; Nervi, B.; Oh, D.Y.; Zhu, A.X. Biliary tract cancer. *Lancet* **2021**, *397*, 428–444. [[CrossRef](#)]
86. Liu, R.; Zhao, R.; Zhou, X.; Liang, X.; Campbell, D.J.W.; Zhang, X.; Zhang, L.; Shi, R.; Wang, G.; Pandak, W.M.; et al. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2. *Hepatology* **2014**, *60*, 908–918. [[CrossRef](#)] [[PubMed](#)]
87. Dai, J.; Wang, H.; Dong, Y.; Zhang, Y.; Wang, J. Bile Acids Affect the Growth of Human Cholangiocarcinoma via NF- κ B Pathway. *Cancer Investig.* **2013**, *31*, 111–120. [[CrossRef](#)]
88. Jia, X.; Lu, S.; Zeng, Z.; Liu, Q.; Dong, Z.; Chen, Y.; Zhu, Z.; Hong, Z.; Zhang, T.; Du, G.; et al. Characterization of gut microbiota, bile acid metabolism, and cytokines in intrahepatic cholangiocarcinoma. *Hepatology* **2019**, *71*, 893–906. [[CrossRef](#)]
89. Chng, K.R.; Chan, S.H.; Ng, A.H.Q.; Li, C.; Jusakul, A.; Bertrand, D.; Wilm, A.; Choo, S.P.; Tan, D.M.Y.; Lim, K.H.; et al. Tissue microbiome profiling identifies an enrichment of specific enteric bacteria in *Opisthorchis viverrini* associated cholangiocarcinoma. *EBioMedicine*. **2016**, *8*, 195–202. [[CrossRef](#)]
90. Deenonpoe, R.; Mairiang, E.; Mairiang, P.; Pairojkul, C.; Chamgramol, Y.; Rinaldi, G.; Loukas, A.; Brindley, P.J.; Sripana, B. Elevated Prevalence of Helicobacter Species and Virulence Factors in Opisthorchiasis and Associated Hepatobiliary Disease. *Sci. Rep.* **2017**, *7*, 42744. [[CrossRef](#)]
91. Xiao, M.; Gao, Y.; Wang, Y. Helicobacter species infection may be associated with cholangiocarcinoma: A meta-analysis. *Int. J. Clin. Pract.* **2014**, *68*, 262–270. [[CrossRef](#)] [[PubMed](#)]

92. Murphy, G.; Michel, A.; Taylor, P.R.; Albanes, D.; Weinstein, S.J.; Virtamo, J.; Parisi, D.; Snyder, K.; Butt, J.; McGlynn, K.A.; et al. Association of seropositivity to *Helicobacter* species and biliary tract cancer in the ATBC study. *Hepatology* **2014**, *60*, 1963–1971. [[CrossRef](#)] [[PubMed](#)]
93. Wheatley, R.C.; Kilgour, E.; Jacobs, T.; Lamarca, A.; Hubner, R.A.; Valle, J.W.; McNamara, M. Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy. *Br. J. Cancer* **2022**, *126*, 693–705. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.